Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 7/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5070893 | 1.00 | GABRA1 (0.35) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL14689525 | 0.74 | AKR1C4 (0.40) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL5069206 | 0.71 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL5069207 | 0.71 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL7157165 | 0.68 | AKR1C4 (0.42) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL5070871 | 0.67 | PDK2 (0.32) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL16954743 | 0.64 | ALDH1A1 (0.52) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL9860364 | 0.64 | GABRA1 (0.48) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL9860368 | 0.64 | GABRA1 (0.48) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| Methoxymethane SCHEMBL28100007 | 0.63 | ALDH1A1 (0.75) | ALDH1A1HPGDTSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5136080-A | Intermediates for glutamate inhibitors | BURROUGHS WELLCOME CO. (US) | 1992-08-04 | — | — | US | claimed |
| EP-1325916-B1 | Piperazinyl-substituted phenyl pyrimidine derivatives useful in the treatment or prevention of disorders of the central nervous system | WELLCOME FOUND (GB) | 2008-01-23 | — | — | EP | disclosed |
| EP-1681058-A2 | Pharmacologically active cns compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 2006-07-19 | — | — | EP | disclosed |
| US-20030044845-A1 | Novel therapeutic agents for membrane transporters | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-03-06 | — | — | US | disclosed |
| US-6479498-B1 | COMPRISE 2-10 SODIUM CHANNEL LIGANDS COVALENTLY CONNECTED BY A LINKER OR LINKERS | THERAVANCE, INC. | 2002-11-12 | — | — | US | disclosed |
| US-6420354-B1 | Sodium channel drugs and uses | ADVANCED MEDICINE, INC. | 2002-07-16 | — | — | US | disclosed |
| WO-1999063984-A9 | NOVEL SODIUM CHANNEL DRUGS AND USES | — | 2002-04-25 | — | — | WO | disclosed |
| WO-1999064045-A9 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | ADVANCED MEDICINE INC (US) | 2001-07-05 | — | — | WO | disclosed |
| EP-1089749-A4 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | ADVANCED MEDICINE INC (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1089749-A1 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | Advanced Medicine, Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-0459819-B1 | Pharmacologically active CNS compound | WELLCOME FOUND (GB) | 1996-08-14 | — | — | EP | disclosed |
| EP-0719244-A1 | PROCESS OF PREPARING 2,3,5-TRIHALOBENZALDEHYDE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-07-03 | — | — | EP | disclosed |
| EP-0715851-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-06-12 | — | — | EP | disclosed |
| EP-0713703-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-05-29 | — | — | EP | disclosed |
| CN-1117046-A | Method for preparing pharmaceutically active CNS compounds | WELLCOME FOUND (GB) | 1996-02-21 | — | — | CN | disclosed |
| EP-0679645-A1 | Pharmacologically active CNS pyridmidin compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-11-02 | — | — | EP | disclosed |
| WO-1995007877-A1 | PROCESS OF PREPARING 2,3,5-TRIHALOBENZALDEHYDE | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-03-23 | — | — | WO | disclosed |
| US-5136080-A | Intermediates for glutamate inhibitors | BURROUGHS WELLCOME CO. (US) | 1992-08-04 | — | — | US | disclosed |
| EP-0459819-A2 | Pharmacologically active CNS compound | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-12-04 | — | — | EP | disclosed |
| EP-0372934-A2 | Pharmacologically active CNS compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044845-A1 | Novel therapeutic agents for membrane transporters | SLC47A2, SLC8B1, SLC47A1 | GABRA1 743/4885GABRG2 650/4885GABRB3 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.